CORRECTION article

Front. Pharmacol., 22 January 2025

Sec. Cardiovascular and Smooth Muscle Pharmacology

Volume 15 - 2024 | https://doi.org/10.3389/fphar.2024.1488083

Corrigendum: Notoginsenoside R1 protects against diabetic cardiomyopathy through activating estrogen receptor α and its downstream signaling

  • 1. Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China

  • 2. Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, China

  • 3. Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Beijing, China

  • 4. Key Laboratory of Efficacy Evaluation of Chinese Medicine Against Glyeolipid Metabolism Disorder Disease, State Administration of Traditional Chinese Medicine, Beijing, China

  • 5. Department of Animal Sciences, Purdue University, West Lafayette, IN, United States

Article metrics

View details

1,2k

Views

418

Downloads

In the published article, there was an error in Figure 2 as published. Specifically, Western blot pictures of HO-1and NQO-1 in Figure 2F were misplaced. After checking the raw data, the misplaced Western blot pictures of HO-1and NQO-1 were corrected. The corrected Figure 2 and its caption appears below.

FIGURE 2

In the published article, there was an error in Figure 3 as published. The TUNEL staining picture in AGEs group was misplaced in Figure 3A. Additionally, the Western blot pictures of Bcl-2 and cleaved casp-3 were misplaced in Figure 3E. After checking the raw data, the misplaced bands of Bcl-2 and cleaved casp-3 were corrected. The corrected Figure 3 and its caption appears below.

FIGURE 3

In the published article, there was an error in Figure 8 as published. The Lamin B1 and β-actin bands in Figure 8C were misplaced. After checking the raw data, the misplaced bands were corrected. The corrected Figure 8 and its caption appears below.

FIGURE 8

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

diabetes mellitus, diabetic cardiomyopathy, estrogen receptor, apoptosis, oxidative stress

Citation

Zhang B, Zhang J, Zhang C, Zhang X, Ye J, Kuang S, Sun G and Sun X (2025) Corrigendum: Notoginsenoside R1 protects against diabetic cardiomyopathy through activating estrogen receptor α and its downstream signaling. Front. Pharmacol. 15:1488083. doi: 10.3389/fphar.2024.1488083

Received

29 August 2024

Accepted

31 December 2024

Published

22 January 2025

Volume

15 - 2024

Edited and reviewed by

Chrishan S. Samuel, Monash University, Australia

Updates

Copyright

*Correspondence: Guibo Sun, ; Xiaobo Sun,

†These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics